SEARCHNARRATIVE_REVIEWophthalmology, preclinical research

narrative_review·ophthalmology, preclinical research, biomedical research, ocular immunology, endocrinology·PMC10185651

Traditional Chinese medicine in thyroid-associated orbitopathy

Journal of Endocrinological Investigation · 4 authors, 3 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This narrative review synthesized preclinical evidence showing that eleven active TCM compounds inhibited orbital fibroblast activity associated with thyroid-associated orbitopathy in vitro, and three of these compounds demonstrated improvement in TAO mouse models. The authors conclude that adequately powered clinical trials are warranted to evaluate the dosage, safety, and efficacy of these compounds in TAO management.

Full summary

353 CHARS

Three compounds (polydatin, curcumin, and gypenosides) additionally showed improvement in TAO mouse models in vivo. The authors note that no human clinical trial data for TAO was included and that clinical trials of different phases with adequate power and sound methodology are warranted to evaluate the dosage, safety, and efficacy of these compounds.

STUDY TYPE

narrative_review

SPECIALTY

ophthalmology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10185651

Traditional Chinese medicine in thyroid-associated orbitopathy

Journal of Endocrinological Investigation

READ THE FULL PAPER

ABSTRACT

Abstract Purpose Orbital fibroblasts (OF) are considered the central target cells in the pathogenesis of thyroid-associated orbitopathy (TAO), which comprises orbital inflammation, orbital tissue edema, adipogenesis, fibrosis, oxidative stress and autophagy. Certain active ingredients of traditional Chinese medicine (TCM) demonstrated inhibition of TAO-OF in pre-clinical studies and they could be translated into novel therapeutic strategies. Methods The pertinent and current literature of pre-clinical studies on TAO investigating the effects of active ingredients of TCM was reviewed using the NCBI PubMed database. Results Eleven TCM compounds demonstrated inhibition of TAO-OF in-vitro and three of them (polydatin, curcumin, and gypenosides) resulted in improvement in TAO mouse models. Tanshinone IIA reduced inflammation, oxidative stress and adipogenesis. Both resveratrol and its precursor polydatin displayed anti-oxidative and anti-adipogenic properties. Celastrol inhibited inflammation and triptolide prevented TAO-OF activation, while icariin inhibited autophagy and adipogenesis. Astragaloside IV reduced inflammation via suppressing autophagy and inhibited fat accumulation as well as collagen deposition. Curcumin displayed multiple actions, including anti-inflammatory, anti-oxidative, anti-adipogenic, anti-fibrotic and anti-angiogenic effects via multiple signaling pathways. Gypenosides reduced inflammation, oxidative stress, tissue fibrosis, as well as oxidative stress mediated autophagy and apoptosis. Dihydroartemisinin inhibited OF proliferation, inflammation, hyaluronan (HA) production, and fibrosis. Berberine attenuated inflammation, HA production, adipogenesis, and fibrosis. Conclusions Clinical trials of different phases with adequate power and sound methodology will be warranted to evaluate the appropriate dosage, safety and efficacy of these compounds in the management of TAO. Keywords: Traditional Chinese medicine, thyroid-associated orbitopathy; Orbital fibroblasts; Autophagy; Inflammation; Oxidative stress

CITATION EXPORT

Y P Hai, A C H Lee, K Chen et al.. Traditional Chinese medicine in thyroid-associated orbitopathy. Journal of Endocrinological Investigation. (2023). https://doi.org/10.1007/s40618-023-02024-4

AUTHORS

4 · 3 CENTRES

Y P Hai, A C H Lee, K Chen, G J Kahaly

1Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Langenbeckstreet 1, 55131 Mainz, Germany
2Department of Endocrinology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, China
3Division of Endocrinology and Metabolism, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China